HUM Quote, Financials, Valuation and Earnings

Amedisys has a net margin of 3.87% compared to Humana's net margin of 10.26%. Humana's return on equity of 10.08% beat Amedisys's return on equity of 7.55%.

Humana has a consensus price target of $303.05, signalling upside risk potential of 31.29%. On the other hand Amedisys has an analysts' consensus of $97.38 which suggests that it could grow by 2.97%. Given that Humana has higher upside potential than Amedisys, analysts believe Humana is more attractive than Amedisys.

Humana has a beta of 0.427, which suggesting that the stock is 57.339% less volatile than S&P 500. In comparison Amedisys has a beta of 0.940, suggesting its less volatile than the S&P 500 by 5.975%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.53%. Amedisys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana pays 35.71% of its earnings as a dividend. Amedisys pays out -- of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $32.1B, which are larger than Amedisys quarterly revenues of $594.8M. Humana's net income of $1.2B is higher than Amedisys's net income of $61M. Notably, Humana's price-to-earnings ratio is 16.32x while Amedisys's PE ratio is 34.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.23x versus 1.32x for Amedisys. Usually stocks with elevated PS ratios are considered overvalued.

CVS Health has a net margin of 3.87% compared to Humana's net margin of 1.88%. Humana's return on equity of 10.08% beat CVS Health's return on equity of 7%.

Humana has a consensus price target of $303.05, signalling upside risk potential of 31.29%. On the other hand CVS Health has an analysts' consensus of $79.49 which suggests that it could grow by 25.04%. Given that Humana has higher upside potential than CVS Health, analysts believe Humana is more attractive than CVS Health.

Humana has a beta of 0.427, which suggesting that the stock is 57.339% less volatile than S&P 500. In comparison CVS Health has a beta of 0.559, suggesting its less volatile than the S&P 500 by 44.102%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.53%. CVS Health offers a yield of 4.18% to investors and pays a quarterly dividend of $0.67 per share. Humana pays 35.71% of its earnings as a dividend. CVS Health pays out 73.1% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $32.1B, which are smaller than CVS Health quarterly revenues of $94.6B. Humana's net income of $1.2B is lower than CVS Health's net income of $1.8B. Notably, Humana's price-to-earnings ratio is 16.32x while CVS Health's PE ratio is 15.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.23x versus 0.21x for CVS Health. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of 3.87% compared to Humana's net margin of 3.51%. Humana's return on equity of 10.08% beat Option Care Health's return on equity of 15.22%.

Humana has a consensus price target of $303.05, signalling upside risk potential of 31.29%. On the other hand Option Care Health has an analysts' consensus of $38.56 which suggests that it could grow by 21.63%. Given that Humana has higher upside potential than Option Care Health, analysts believe Humana is more attractive than Option Care Health.

Humana has a beta of 0.427, which suggesting that the stock is 57.339% less volatile than S&P 500. In comparison Option Care Health has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.903%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.53%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana pays 35.71% of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $32.1B, which are larger than Option Care Health quarterly revenues of $1.3B. Humana's net income of $1.2B is higher than Option Care Health's net income of $46.7M. Notably, Humana's price-to-earnings ratio is 16.32x while Option Care Health's PE ratio is 25.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.23x versus 1.04x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

OptimizeRx has a net margin of 3.87% compared to Humana's net margin of -10.03%. Humana's return on equity of 10.08% beat OptimizeRx's return on equity of -13.03%.

Humana has a consensus price target of $303.05, signalling upside risk potential of 31.29%. On the other hand OptimizeRx has an analysts' consensus of $15.08 which suggests that it could grow by 14.1%. Given that Humana has higher upside potential than OptimizeRx, analysts believe Humana is more attractive than OptimizeRx.

Humana has a beta of 0.427, which suggesting that the stock is 57.339% less volatile than S&P 500. In comparison OptimizeRx has a beta of 1.337, suggesting its more volatile than the S&P 500 by 33.676%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.53%. OptimizeRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana pays 35.71% of its earnings as a dividend. OptimizeRx pays out -- of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $32.1B, which are larger than OptimizeRx quarterly revenues of $21.9M. Humana's net income of $1.2B is higher than OptimizeRx's net income of -$2.2M. Notably, Humana's price-to-earnings ratio is 16.32x while OptimizeRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.23x versus 2.57x for OptimizeRx. Usually stocks with elevated PS ratios are considered overvalued.